February 5, 2024

In a head-to-head study, the triplet therapy of belantamab mafodotin (belamaf) plus bortezomib, and dexamethasone (BVd) demonstrated a significantly improved progression-free survival compared to the current standard of care in patients with relapsed or refractory multiple myeloma. These results will be presented during the February 2024 session of the American Society of Clinical Oncology (ASCO) Plenary Series.

February 5, 2024

Results from a new phase 3 study conducted in China demonstrated a significant improvement in progression-free survival in patients with advanced stomach cancers. According to the authors, this is the first phase 3 trial to demonstrate survival benefits with a new treatment alternative to ramucirumab-containing therapy in the second-line setting for patients with advanced gastric or gastroesophageal junction adenocarcinoma. These results will be presented during the February 2024 session of the American Society of Clinical Oncology (ASCO) Plenary Series.

January 27, 2024

The phase 3 KEYNOTE-564 study has reported that adjuvant pembrolizumab provides a significant improvement in overall survival for patients with clear cell renal cell carcinoma (ccRCC) at high risk of recurrence after surgery. This study is significant as it represents the first phase 3 study to show improved overall survival with any adjuvant therapy in kidney cancer. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27 in San Francisco, California. 

January 22, 2024

Patients with metastatic castration-resistant prostate cancer (mCRPC) with extrapelvic nodal or visceral metastasis who were treated with the combination therapy of cabozantinib plus atezolizumab had significantly improved time to disease progression compared to those who were treated with hormonal therapy. This research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27 in San Francisco, California.

January 20, 2024

Ten studies exploring new approaches for the treatment of gastrointestinal cancers will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place in San Francisco, CA, and online, January 18-20. 

January 19, 2024

The addition of durvalumab and bevacizumab to TACE significantly improved progression-free survival in patients with unresectable hepatocellular carcinoma (uHCC) that were eligible for embolization. According to the authors, this is the first trial to demonstrate improved clinical outcomes for immunotherapy-based combinations with TACE in these patients. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California and online.

January 19, 2024

Results from the first phase 3 clinical trial evaluating radioligand therapy in the first-line setting demonstrated that treatment with [177Lu]Lu-DOTA-TATE significantly improved progression-free survival and objective response rates in patients with high-grade gastroenteropancreatic neuroendocrine tumors, potentially establishing a new standard of care. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California. 

January 16, 2024

The role of ctDNA, or liquid biopsy, as a predictive tool to guide and monitor cancer treatment, remains unclear after the first prospective randomized phase II trial evaluating clearance of ctDNA as a primary endpoint using adjuvant chemotherapy in patients with stage II colon cancer did not meet its endpoint. The NRG-GI005 (COBRA) phase II/III study was halted after the results of the pre-planned phase II analysis found that the use of chemotherapy did not increase the rate of ctDNA clearance among patients who had detectable ctDNA after surgery when compared to patients who did not receive chemotherapy. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California and online.

January 16, 2024

Following surgery to remove a tumor, patients may have molecular residual disease (MRD), or a small amount of cancer cells that remain in the body but are too small to be detected with imaging. ctDNA, or liquid biopsy, may be used to detect MRD in patients who underwent surgery for colorectal cancer and determine if they will benefit from receiving adjuvant chemotherapy. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California.

January 16, 2024

Results from a new phase III study found that combining PD-L1and TIGIT inhibitors plus chemotherapy in the first-line setting prolongs survival in an Asian population of patients with metastatic or locally advanced esophageal squamous cell carcinoma. This treatment combination has the potential to boost the body's ability to fight cancer and may ultimately lead to better outcomes for these patients with esophageal squamous cell carcinoma that cannot be surgically removed or has spread to other parts of the body. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco, California. 

January 10, 2024

The latest research exploring innovative approaches for the detection and treatment of prostate, bladder, and kidney cancers will be highlighted in the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the more than 700 abstracts that will be presented at the meeting.

December 19, 2023

Six studies exploring new approaches for the treatment of gastrointestinal cancers will be highlighted in the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium’s official Press Program. The research includes circulating tumor DNA (ctDNA) in colorectal cancer and new treatment options for pancreatic, liver, and esophageal cancers. Studies featured in the Press Program are among the more than 750 abstracts that will be presented at the Symposium.

November 6, 2023

The addition of the T-cell immunoglobulin and ITM domain (TIGIT) inhibitor domvanalimab to the programmed cell death protein 1 (PD-1) inhibitor zimberelimab and chemotherapy may improve outcomes for patients with advanced gastroesophageal cancer. These results will be presented during the November 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.

November 6, 2023

A first-in-class antibody-drug conjugate called CMG901 targeting claudin 18.2 (also referred to as CLDN18.2) may be a potential new treatment option for patients with claudin 18.2-positive gastric or gastroesophageal junction cancer. These results will be presented during the November 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.

October 23, 2023

A new interventional study found that participation in virtual mind-body fitness classes reduced hospitalizations, length of hospital stays, and urgent care visits by half. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium taking place October 28-29 in Boston. 

Pages